Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal
Related Experiment Video
Updated: Mar 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Fabio Marsico1, Milena Cecere1, Antonio Parente1
1Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
Insights
Novel oral anticoagulants show promise in treating left atrial appendage thrombosis in patients with atrial fibrillation (AF). This review summarizes current evidence on their effectiveness for this condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common arrhythmia increasing stroke risk.
- Left atrial appendage thrombi are frequent in AF patients.
- Vitamin K antagonists were historically the primary anticoagulants.
Purpose of the Study:
- To review the effectiveness of novel oral anticoagulants (NOACs) in treating left atrial appendage thrombosis.
- To summarize current evidence on NOACs for AF-related thrombosis.
Main Methods:
- Literature search for studies on NOACs and left atrial appendage thrombosis.
- Synthesis of available evidence on NOAC efficacy and safety.
Main Results:
- Limited data currently exist on NOACs for left atrial appendage thrombosis.
- Further research is needed to establish definitive efficacy.
Conclusions:
- Novel oral anticoagulants may offer an alternative for managing left atrial appendage thrombosis in AF.
- More clinical data are required to confirm their role.
Abstract:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and predisposes to an increased risk of thromboembolic events. Patients affected by AF exhibit an increased risk of stroke compared with those in sinus rhythm, with the most common location of thrombi in the left atrial appendage. Until 2009, warfarin and other vitamin K antagonists were the only class of oral anticoagulants available. More recently, dabigatran, rivaroxaban, apixaban, and edoxaban have been approved by regulatory authorities for prevention of stroke in patients with non-valvular AF. Few data are available about the efficacy of novel oral anticoagulants for the treatment of left atrial and left atrial appendage thrombosis. Aim of this review is to summarize available evidence regarding the effectiveness of novel oral anticoagulants on left atrial appendage thrombosis.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction
Clot Retraction and Fibrinolysis